Full List Of Stories
London close: Stocks maintain gains ahead of UK jobs data
London markets closed higher on Monday, with Croda International among the leaders after the specialty chemicals company reported a strong third-quarter sales update.
Pantheon Resources announces spudding of Megrez-1 well
Pantheon Resources announced the spudding of the Megrez-1 well on Alaska’s North Slope on Monday, targeting the eastern topsets in the Ahpun field.
Team Internet revenue rises, profit before tax falls
Team Internet reported a 1% improvement in gross revenue in the first three quarters of the financial year on Monday, to $615. 1m, while net revenue increased 4% to $143. 6m, bolstered by a rise in gross margins from 22. 6% to 23. 3%.
Science Group on track for record full-year adjusted profit
Science Group announced on Monday that it remains on track to achieve record adjusted operating profit for the 2024 financial year, meeting market expectations.
Westminster Group confirms it's not seeking AIM delisting
Westminster Group clarified in a statement on Monday that it was not considering a cancellation of its AIM listing in London, despite recent media speculation.
Director dealings: Arcontech CEO invests, Hargreaves Services director conducts sale-and-repurchase
Matthew Jeffs, chief executive officer of Arcontech Group, disclosed a series of personal share purchases in the company on Monday, amounting to a total of 60,000 ordinary shares.
Seeing Machines reports strong growth in installations
Driver monitoring technology company Seeing Machines reported strong growth in its quarterly key performance indicators for the first quarter of the 2025 financial year on Monday.
Faron Pharmaceuticals files new patent for Clever-1
Faron Pharmaceuticals, a clinical-stage biopharmaceutical company specialising in immunotherapies for cancer and inflammatory diseases, announced the filing of a new patent application for the use of soluble Clever-1 in targeting T-cell inactivation on Monday, with potential applications in treating autoimmune diseases and inflammatory disorders.
Caledonia Mining reports mixed third quarter
Caledonia Mining reported a mixed third-quarter financial and operational performance on Monday, driven by fluctuations in gold production, rising costs, and encouraging exploration outcomes at its Zimbabwe-based assets.
PRS REIT amends agreement with adviser amid strategic review
Private rental sector-focussed new build investor PRS REIT announced an amendment to its investment advisory agreement with Sigma PRS Management, its investment adviser, on Monday.
Forterra confident despite challenging trading conditions
Clay and concrete building products manufacturer Forterra reported challenging trading conditions for the four months to the end of October on Monday.
International Personal Finance subsidiary gets full Polish licence
International Personal Finance announced on Monday that its Polish home credit subsidiary, Provident Polska, has secured a full payment institution licence from Poland’s financial supervisory authority, the Komisja Nadzoru Finansowego (KNF).
Asia report: Markets mixed as China stimulus fails to excite
Asia-Pacific markets showed a mixed performance on Monday as China’s latest economic data and a newly announced five-year stimulus package failed to inspire investor confidence.
Bitcoin tops $82,000 level in early Monday trading
Bitcoin has surged well past the $80,000 mark for the first time, propelled by investor optimism following Donald Trump’s US election victory, with expectations that his administration would support a friendlier regulatory environment for digital currencies.
RHI Magnesita reports continued weak demand conditions
RHI Magnesita reported a steady third-quarter performance amid challenging demand conditions in an update on Monday, as it warned of softer full-year sales than previously expected.
Syncona's Autolus gets FDA approval for leukaemia treatment
Life science investor Syncona announced on Monday that its portfolio company Autolus Therapeutics has received US Food and Drug Administration (FDA) approval for Aucatzyl (obe-cel), a CAR T-cell therapy developed for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL).
NatWest buys back £1bn of shares from state, Syncona's Autolus gets FDA nod
London open The FTSE 100 is expected to open 45 points higher on Monday, having closed down 0. 84% on Friday at 8,072. 39.